Clinical trialObservationalCompleted
Patient Reported Outcomes Registry in Patient With Cancer Cachexia
Tablet-based Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced NSCLC or Advanced Pancreatic Cancer With Focus on Cancer Cachexia
- Outcome
- Finished, no results posted
- Phase
- Observational
- Status
- Completed
- Study type
- Observational
- Start
- 28 August 2016
- Ended
- 24 July 2019
- Enrollment
- 253 participants
- Sites
- 1
- Primary outcomes
- Rate of patients with loss of > 5 % body weight
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 7 August 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.
Detailed description public domain (ClinicalTrials.gov)
The PRO Xie project will recruit a representative cohort of patients with advanced lung or advanced pancreatic cancer with a high risk for the development of cancer cachexia. Patient Reported Outcomes (PRO) are assessed in a real life setting by a questionnaire consisting of 20 questions: QoL is measured by SF12, fatigue by FACIT-F and cachexia by FAACT questionnaires, respectively. These data will determine the potential need for anti-cachexia treatment in those patients, as well as the number of underweight patients, the evaluation of general QoL, fatigue and cachexia and the evaluation of malnutrition.